Teresa López-Fernández is a clinical investigator and senior consultant cardiologist at the University Hospital of La Paz in Madrid, Spain. Dr López-Fernández specialises in cardiac imaging and cardio-oncology. Dr López-Fernández coordinates the Cardio-Oncology Clinic at the University Hospital of La Paz. She is the founder and president of the Spanish Cardio-Oncology Working Group of the Spanish Society of Cardiology (SEC). She is also vice-president of the International Cardio-Oncology Society (ICOS) and was elected president of the ESC Council for Cardio-Oncology. Dr López-Fernández is co-chair of the ESC Guidelines on Cardio-Oncology 2022. Her current research interests focus on the diagnosis and prevention of cardiotoxicity.

After his MD and Ph degrees in Medicine (1981) and Oncology (1984) Dr. Minotti has been Fellow of the Italian Association for Cancer Research, Fulbright Scholar and Fulbright Visiting Professor at Michigan State University, East Lansing, MI (9/1985-1/1987), and Case Western Reserve University, Cleveland, OH (6/1990-6/1991). He currently is Professor of Pharmacology at the Department of Medicine and Fondazione Policlinico Universitario, Campus Bio-Medico University of Rome. Dr. Minotti has authored over 150 full papers in Medline-based journals, mostly focusing on pharmacokinetic and pharmacodynamic correlates of cardiotovascular toxicity of cancer drugs. He is Editor-in-Chief of Chemotherapy, Deputy Editor di Cardio-Oncology, Editorial Board Member di J. Pharmacol. Expt. Ther.

Dr. SivaTharshini Ramalingam is an ICOS board-certified Cardio-Oncology Specialty doctor at The Royal Brompton Hospital, London and a GP Partner at Oxted Health Centre in Surrey. She graduated from University College London and has a postgraduate diploma in Heart Failure Management from the world-renown Zurich Heart House and a postgraduate diploma in Cardiology from the University of Plymouth. Uniquely, the first GP with a special interest in Cardio-Oncology, she is the national GP lead for the British Cardio-Oncology society. Furthermore, she is a Faculty Member and Clinical Advisor to the Royal College of General Practitioners and a member of the Royal College of Physicians of London. She is also a council member of the Royal Society of Medicine. Dr Ramalingam is an ardent champion of the holistic care of patients with chronic diseases such as cancer and heart failure.

Richard Stephens has survived (so far) two cancers, a heart emergency, and continued co-morbidities and late effects. He has participated in four interventional studies and fourteen others and has donated tissues and samples for research.

Richard is in his third decade as a Patient Advocate, and is currently NCRI's Consumer Involvement Lead. He has chaired and sits on strategic groups in Europe and the UK, including BBMRI-ERIC, NHS England, NIHR, Genomics England and Cancer Research UK, and works with industry and with patient groups in Europe, Canada and the USA.

Richard was the patient co-author of the 2015 Cancer Strategy for England, and was an advisor to the UK government during the pandemic. He was the patient lead for the UK’s Living With And Beyond Cancer research priority-setting project, with a particular interest in late effects, in view of his own heart problems.

Richard is the founding co-Editor-in-Chief of the Journal of Research Involvement and Engagement, the patient co-author of ESC Guidelines on cardio-oncology, and a member of ESC’s Patient Forum.

Thomas Suter is board-certified in cardiology and internal medicine and the head of the Department of Internal Medicine at Lindenhofgruppe in Bern, Switzerland. In addition, he leads the Cardio-Oncology Service and is a member of the section for heart failure and cardiac transplantation at the University Hospital Bern. He received his medical degree from the University of Zurich and took residency training in internal medicine and cardiology at University Hospital Zürich, Boston University Medical Center and Brigham and Women’s Hospital, Boston MA. During his cardiology training, he specialized on heart failure and cardiac transplantation. His clinical research during the past 20 years focused on the investigation of cardiovascular side effects of cancer therapeutics. He currently serves as the chair of the Council on Cardio-Oncology of the European Society of Cardiology and on several steering committees of multinational cancer trials. Furthermore, he is directing a basic research lab in which he investigates mechanisms of chemotherapeutic-associated cardiotoxicity. His publications include over 100 articles on heart failure, cancer drug-associated cardiovascular side effects and general cardiology and more than 20 books on general and internal medicine.

Selected publications:
Cardio-oncology in clinical studies and real life. Dent SF, Suter TM, Minotti G et al. Semin Oncol. 2019 Dec;46(6):421-425

Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab.
Lenihan D, Suter T, Baselga J et al. Ann Oncol. 2019 Jun 1;30(6):1021.

Modern-day cardio-oncology: a report from the 'Heart Failure and World Congress on Acute Heart Failure 2018'. Anker MS, Suter T, Lyon AR et al. Heart Failure Association Cardio-Oncology Study Group of the European Society of Cardiology. ESC Heart Fail. 2018 Dec;5(6):1083-1091

Cardio-Oncology Services: rationale, organization, and implementation.
Lancellotti P, Suter TM, Asteggiano R et al. Eur Heart J. 2019 Jun 7;40(22):1756-1763.

Cancer diagnosis in patients with heart failure: epidemiology, clinical implications and gaps in knowledge. Ameri P, Suter T, Tocchetti CG et al. Heart Failure Association Cardio-Oncology Study Group of the European Society of Cardiology. Eur J Heart Fail. 2018 May;20(5):879-887

Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06). Ponde N, Suter T, de Azambuja E et al. Breast Cancer Res Treat. 2018 Apr;168(3):631-638.

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. von Minckwitz G, Suter T, Baselga J et al. N Engl J Med. 2017 Jul 13;377(2):122-131.

Role of Troponins I and T and N-Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients With Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Trastuzumab: A Herceptin Adjuvant Study Cardiac Marker Substudy. Zardavas D, Suter TM, de Azambuja E et al. J Clin Oncol. 2017 Mar 10;35(8):878-884.

2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Zamorano JL, Lancellotti P, Suter TM et al.; ESC Scientific Document Group. Eur Heart J. 2016 Sep 21;37(36):2768-2801.

Prof. Carlo Gabriele Tocchetti is currently Associate Professor of Medicine in the Department of Translational Medical Sciences, Federico II University, Naples, Italy since 2014, where he is Director of the Internal Medicine Unit for cancer patients and has established himself as a HF basic and clinical investigator. Prof Tocchetti is President, International Cardio-Oncology Society (ICOS) Italy Chapter, Fellow of the HFA, Chair of the Basic Science Section of the HFA, and Board member of the ESC Council on Cardio-Oncology.

The main goal of his lab is to explore pathophysiologic mechanisms and therapeutic targets in cardiac dysfunction, with a particular interest on post-ischemic HF, genetic and inflammatory cardiomyopathies, Pulmonary Hypertension and RV dysfunction, and HF due to antineoplastic therapies, including novel anticancer immunotherapies and biologic drugs employed in inflammatory diseases.

Jose L. Zamorano is Professor of Medicine at the University Alcala de Henares, Madrid, Spain, and the Chief of Cardiology at the University Hospital Ramón y Cajal, Spain.

Professor Zamorano obtained his medical degree from the University Complutense in 1987 and his Doctor of Medicine in 1991. He received his board certification in cardiology in 1993 before joining the Complutense University as an Associate Professor.

Professor Zamorano has served as Secretary of the European Society of Cardiology (ESC), President of the European Association of Echocardiography, International Advisor of the American College of Cardiology’s International Committee, Director of the scientific programme in imaging for the ESC Congress, and member of the Practice Guidelines Committee of the ESC and Vicepresident ESC

Over the past 20 years, Professor Zamorano has received a number of prestigious awards, including the Golden Plaque of the Public Health Authorities of Madrid and the Ingel Edler Gold Medal, the Silver Medal of the ESC and the Research Award of the Spanish Society of Cardiology. He has served on numerous editorial boards of journals and is currently Associate Editor of the European Journal of Cardiovascular Imaging.

Professor Zamorano has a broad range of research interests including heart failure, ischaemic heart disease, cardiovascular risk factors and cardiovascular imaging modalities. Within these fields, he has published over 700 articles and 20 books, including the European Textbook of Cardiovascular Imaging. His impact factor is over 1500 and he has a Hirsch Index of 121, with more than 120,000 citations.